These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2970222)

  • 1. The influence of body weight on lipoprotein lipids in patients with polycystic ovary syndrome.
    Wild RA; Bartholomew MJ
    Am J Obstet Gynecol; 1988 Aug; 159(2):423-7. PubMed ID: 2970222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables.
    Holte J; Bergh T; Berne C; Lithell H
    Clin Endocrinol (Oxf); 1994 Oct; 41(4):463-71. PubMed ID: 7955457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid profiles in women with hirsutism and polycystic ovaries.
    Senöz S; Ozaksit G; Turhan NO; Gülekli B; Gökmen O
    Gynecol Endocrinol; 1994 Mar; 8(1):33-7. PubMed ID: 8059615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome.
    Wild RA; Painter PC; Coulson PB; Carruth KB; Ranney GB
    J Clin Endocrinol Metab; 1985 Nov; 61(5):946-51. PubMed ID: 4044782
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of heterogeneous mechanisms in lipoprotein lipid alterations in hyperandrogenic women.
    Wild RA; Bartholomew M; Applebaum-Bowden D; Demers LM; Hazzard W; Santen RJ
    Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1998-2005. PubMed ID: 2256513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of combined desogestrel-ethinylestradiol treatment on lipid profiles in women with polycystic ovarian disease.
    Rojanasakul A; Chailurkit L; Sirimongkolkasem R; Chaturachinda K
    Fertil Steril; 1987 Oct; 48(4):581-5. PubMed ID: 2958365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormalities of fuel metabolism in the polycystic ovary syndrome.
    Wortsman J; Soler NG
    Obstet Gynecol; 1982 Sep; 60(3):342-5. PubMed ID: 6214733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
    Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
    Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma thiols and androgen levels in polycystic ovary syndrome.
    Vrbíková J; Tallová J; Biciková M; Dvoráková K; Hill M; Stárka L
    Clin Chem Lab Med; 2003 Feb; 41(2):216-21. PubMed ID: 12667010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of weight loss on inflammation in obese women with polycystic ovary syndrome.
    Olszanecka-Glinianowicz M; Zahorska-Markiewicz B; Kocełak P; Janowska J; Semik-Grabarczyk E
    Endokrynol Pol; 2008; 59(1):13-7. PubMed ID: 18335395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relations of serum adipocyte fatty acid binding protein to sex hormone and lipoproteins in patients with polycystic ovary syndrome].
    Hu WH; Qiao J; Li R; Wang LN
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(45):3186-9. PubMed ID: 17313783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Obesity, hormonal and metabolic abnormalities in adolescent girls with polycystic ovary syndrome].
    Ságodi L; Lombay B; Vámosi I; Barkai L
    Orv Hetil; 2013 Aug; 154(31):1226-34. PubMed ID: 23895991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome].
    Li X; Lin JF
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(46):3266-71. PubMed ID: 16409817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
    Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
    J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Role of Serum Cystatin C Levels in Polycystic Ovary Syndrome in Adolescents.
    Çınar M; Aksoy RT; Güzel Aİ; Tokmak A; Çandar T; Taşçı Y
    J Pediatr Adolesc Gynecol; 2016 Aug; 29(4):353-6. PubMed ID: 26740281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
    Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
    Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dehydroepiandrosterone sulfate as a prehormone for ovarian steroidogenesis.
    Haning RV; Austin CW; Carlson IH; Kuzma DL; Zweibel WJ
    Obstet Gynecol; 1985 Feb; 65(2):199-205. PubMed ID: 3155830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examination of angiopoietin-like protein 4, neuropeptide Y, omentin-1 levels of obese and non-obese patients with polycystic ovary syndrome.
    Güneş M; Bukan N
    Gynecol Endocrinol; 2015; 31(11):903-6. PubMed ID: 26291814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in serum lipids, lipoproteins, sex hormone binding globulin and testosterone between the follicular and the luteal phase of the menstrual cycle.
    Schijf CP; van der Mooren MJ; Doesburg WH; Thomas CM; Rolland R
    Acta Endocrinol (Copenh); 1993 Aug; 129(2):130-3. PubMed ID: 8372597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.